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Abstract
The favourable effects of probiotics on human health have already been well documented. Their application in prophy-
laxis and therapy, especially of inflammatory diseases of alimentary tract (including antibiotic-associated diarrhoea) is 
not questioned any more. This study presents current data on the knowledge of the suitability of probiotic strains of the 
Lactobacillus genus for application in dentistry in adults with dental caries or chronic periodontitis. In the light of recent 
in vitro and in vivo studies, antagonistic effects of lactobacilli producing hydrogen peroxide toward cariopathogens and 
periopathogens were reviewed. The potential was analysed for using probiotic Lactobacillus strains in dentistry, poin-
ting to their significance in prophylaxis and therapy of caries and chronic periodontitis. 
Keywords: probiotics, Lactobacillus, dental caries, chronic periodontitis.
Streszczenie
Dobrze już udokumentowano korzystne oddziaływanie probiotyków na zdrowie człowieka. Ponadto, ich zastosowanie 
w profilaktyce i terapii, przede wszystkim chorób zapalnych przewodu pokarmowego (w tym biegunce związanej z an-
tybiotykoterapią), nie budzi dziś wątpliwości. W tej pracy przedstawiono dane dotyczące aktualnego stanu wiedzy w za-
kresie przydatności stosowania szczepów probiotycznych z rodzaju Lactobacillus w stomatologii, u osób dorosłych 
z próchnicą zębów lub przewlekłym zapaleniem przyzębia. Omówiono, w świetle najnowszych badań in vitro i in vivo, 
antagonistyczne oddziaływanie pałeczek Lactobacillus wytwarzających nadtlenek wodoru wobec kariopatogenów oraz 
periopatogenów. Jednocześnie analizowano możliwości zastosowania probiotycznych szczepów Lactobacillus w sto-
matologii, wskazując na ich znaczenie w profilaktyce i terapii próchnicy oraz przewlekłego zapalenia przyzębia. 
Słowa kluczowe: probiotyki, Lactobacillus, próchnica zębów, przewlekłe zapalenie przyzębia.
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In line with the current WHO definition, probiotics 
involve living microbes which, administered per os 
to humans exert favourable health effects, inde-
pendently of basic food [1]. This basic definition 
was supplemented with the so called criteria of 
Fuller: the probiotic agent should not be pathoge-
nic nor be toxic for human body, manifesting no 
immune disturbances [2]. Thus, the probiotic strain 
should have GRAS (generally recognised as safe) 
status and safety of its application should be sup-
ported by in vitro and in vivo studies [3].
The probiotic strains include mainly lactic acid 
bacilli of Lactobacillus and Bifidobacterium genera 
and Saccharomyces boulardii yeasts. The probio-
tic strains used in dentistry include Lactobacillus 
reuteri, L. brevis, L. rhamnosus GG, L. paracasei, 
L. acidophilus, L. plantarum and Bifidobacterium 
longum. The genus of Lactobacillus covers a he-
terogenous group of over 100 species of Gram(+) 
bacilli, widely present in the natural environment 
(Figure 1). At the same time the bacilli compose 
the microbiotas of humans and animals [3].
The favourable effect of probiotics on human 
health has already been well documented [4–8]. 
Moreover, their application in prophylaxis and 
therapy, particularly of alimentary tract diseases 
(including antibiotic-associated diarrhoea) is not 
questioned any more [9–11]. The antineoplastic 
activity of probiotic strains is also indicated [12]. 
The European SYNCAN project is implemented 
Figure 1. Lactobacillus acidophilus in Gram staining 
(1000x)
Rycina 1. Lactobacillus acidophilus w preparacie bar-
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to analyse the antineoplastic action of probiotic 
agents [13].
The first studies on the application of probiotic 
agents in dentistry involved investigations on den-
tal caries, conducted in 2001 on children with ac-
tive caries. Supplementation of the diet with milk 
containing L. rhamnosus strain was found to re-
duce the course of the disease [14]. The results 
were followed by introduction of probiotics in to 
prophylaxis and therapy of dental caries as sup-
plementary preparations. 
Dental caries represents a restricted patholo-
gical process, induced by oral cavity bacteria, re-
sulting in demineralization and destruction of solid 
dental tissues with development of a carious de-
fect [15]. Global population studies confirmed uni-
versal worldwide manifestation of dental caries, 
representing the most frequent disease of civiliza-
tion-linked nature [16, 17]. Much higher levels of 
caries occurred in adults than in children in all 26 
countries all over the world. In Europe the highest 
indices of DMFT were detected in its north-western 
part, particularly in Poland, Finland, Denmark and 
Austria [18]. Etiopathogenesis of early carious le-
sion is determined mainly by activity of caries-in-
ducing streptococci of Streptococcus genus, inc-
luding S. mutans (the Mutans group). The species 
is recognised to represent a classical cariopatho-
gen. Bacteria of the species manifest the ability to 
produce soluble and insoluble extracellular poly-
saccharides (dextran, fructan), forming stroma of 
developing dental plaque [19]. Other cariopatho-
gens include Streptococcus salivarius (the Saliva-
rius group) and Streptococcus sanguinis (the Mitis 
group). In such bacteria the sugars supplied with 
food are rapidly metabolized to organic acids. The 
arising organic acids become accumulated in den-
tal plaque, reducing its pH to less than 5.5, which 
initiates the development of an early lesion focus.
The published papers pointing to the favo-
urable clinical effect of probiotics administration 
in dental caries justify further studies. Therefore, 
in my studies I analysed the in vitro potential for 
an antagonistic effect of Lactobacillus spp. ba-
cilli against Streptococcus mutans [20]. The stu-
dies were conducted on 120 patients aging 20 to 
49 years, in two groups. Group 1 comprised 45 
persons with active caries and group 2 included 
75 caries-free persons. The activity of caries was 
assessed using WHO criteria, including DMFT, GI 
(Gingival Index) and PLI (Plaque Index) [17]. The 
investigated material involved samples of saliva 
at rest, in which manifestation of Lactobacillus 
bacteria was examined and their ability to produ-
ce hydrogen peroxide. Isolation of Lactobacillus 
strains and estimation of their ability to produce 
hydrogen peroxide were conducted in the Depart-
ment of Medical Microbiology, Poznan University 
of Medical Sciences. Strains of Lactobacillus spp. 
were identified using API 50 CHL test (bioMerieux) 
while the ability to produce hydrogen peroxide was 
determined by culturing the isolates in a differen-
tiating medium of TMB-Plus agar, prepared as de-
scribed by Rabe and Hillier [21], as illustrated in 
figures 2 and 3. The tests permitted to find out 
that in all patients with active caries the isolated 
bacilli of Lactobacillus did not produce hydrogen 
peroxide. In the group of caries-free persons stra-
ins of Lactobacillus isolated from 35% of patients 
did not produce hydrogen peroxide while in 27.5% 
of patients the presence of Lactobacillus spp. co-
uld not be demonstrated.
The obtained results may indicate that activi-
ty of caries is linked to presence of Lactobacillus 
spp. strains producing no hydrogen peroxide. On 
the other hand, it is known oral lactobacilli are that 
they may play a significant role in the progression 
of dental caries, which is mainly linked to produc-
tion by the bacteria of lactic acid [22, 23]. Results 
of my studies are consistent with the data and for 
the first time they document the pathogenetic re-
lationship between active caries and presence of 
Lactobacillus spp. strains producing no hydrogen 
Figure 3. Lactobacillus acidophilus strain non-produ-
cing hydrogen peroxide on TMB-Plus medium
Rycina 3. Szczep Lactobacillus acidophilus nie wytwa-
rzający H2O2 na podłożu różnicującym TMB-Plus
Figure 2. Lactobacillus acidophilus strain producing hy-
drogen peroxide on TMB-Plus medium
Rycina 2. Szczep Lactobacillus acidophilus wytwarzają-
cy H2O2 na podłożu różnicującym TMB-Plus
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peroxide. Salivary manifestation of Lactobacillus 
spp. bacteria producing hydrogen peroxide was 
demonstrated already earlier [24–25]. However, 
the obtained results were not analysed in compa-
rison to activity of the carious process. 
Continuing the studies on the role of probiotics 
in diseases of oral cavity I addressed the problem 
of antagonistic interactions between clinically im-
portant periopathogens and strains of Lactobacil-
lus spp. in microflora of oral cavity in chronic pe-
riodontitis in adults [26–29].
Chronic periodontitis is an inflammatory dise-
ase, leading to destruction which involves gingi-
vae, radical cementum, periodontium and osseous 
alveolus. Chronic periodontitis has a moderate or 
severe clinical course. Incidence of the disease 
and its severity increase with age [30]. Epidemiolo-
gical investigations confirm that chronic periodon-
titis belongs to the most frequent chronic diseases 
in humans. In western Europe in around 36% of 
persons aged 35 to 44 years a moderate and in 
around 10% a severe form of the disease is reve-
aled; in eastern Europe the proportions are higher, 
45% and 30–40% respectively. In Poland a mode-
rate form of chronic periodontitis was diagnosed 
in around 32% of persons and a severe form in 
around 16% of individuals [31]. 
The principal etiological factor of chronic pe-
riodontitis involves plaque-forming bacteria, de-
fined as periopathogens. Bacteria of the plaque 
exert harmful effects on fibroblasts, epithelial cells 
and endothelial cells and on components of extra-
cellular substance. Also, they may affect cells of 
the immune system, stimulating them to produce 
mediators of inflammatory reactions [32–34]. Cur-
rently, on the basis of studies of Socransky’s team 
specific groups of bacterial species are distingu-
ished (termed complexes) with particular signifi-
cance for etiopathogenesis of chronic periodon-
titis [35]. Porphyromonas gingivalis, together with 
the species of Tannerella forsythia and Treponema 
denticola, form the so-called red complex, which 
seems to be linked to pathogenic signs of perio-
dontitis in adults [36, 37]. Another significant group 
of bacteria forms the so-called orange complex, 
encompassing 13 species, including Fusobacte-
rium nucleatum and Prevotella intermedia, mani-
festing a particular pathogenetic significance. Mi-
crobiological investigations indicate that bacteria 
of the orange complex form an indispensable link, 
promoting colonization on periodontal tissues by 
the red complex. Another group of bacteria forms 
the so-called green complex, comprising three 
species: Capnocytophaga sputigena, C. gingivalis 
and Eikenella corrodens [37]. The species are also 
associated with morbid signs of chronic periodon-
titis in adults but induce a more benign clinical co-
urse, as compared to that induced by red complex 
bacteria. Moreover, separate periopathogens are 
distinguished, in particular Aggregatibacter acti-
nomycetemcomitans, which may accompany the 
red complex. Currently, a particular significance of 
A. actinomycetemcomitans is recognised in etio-
pathogenesis of periodontitis [38, 39].
The data have inspired me to undertake studies 
on the potential for antagonistic effects of probio-
tics against periopathogens [29]. The studies were 
conducted on 30 patients, 35 to 49 years of age, in 
two separate groups. Group 1 involved 16 patients 
with moderate chronic periodontitis while group 2 
consisted of 14 patients with severe chronic pe-
riodontits. The control group included healthy pa-
tients, 20 to 42 years of age. Chronic periodontitis 
was diagnosed in line with WHO criteria [17, 40]. In 
the studies of the saliva of all patients with mode-
rate chronic periodontitis hydrogen peroxide-pro-
ducing bacilli of Lactobacillus spp. were identified. 
The hydrogen peroxide-producing bacilli of Lacto-
bacillus spp. were demonstrated only in patients 
with the moderate form of chronic periodontitis.
The present data indicate that in pathogenesis 
of periodontitis a significant role is played by pro-in-
flammatory cytokine response of Th 17, expressed 
by high levels of IL-17 and TNF-α in gingival fluid 
of patients with chronic periodontitis [41, 42]. IL-17 
induces activation of neutrofiles with inflammatory 
reaction, which additionally accentuates synergic 
interaction of TNF-α, IL-22 and IL-26. Moreover, 
IL-17 releases neutrofiles while IL-22 induces anti-
bacterial peptides, involving a nonspecific immune 
response against bacterial and mycotic pathogens 
[43, 44]. Thus, the cytokine response of Th17 ful-
fils an important role in immune protection of the 
host and it may provide the principal mediator in 
pathogenesis of several inflammatory diseases, as 
indicated by results of recent studies [45–48]. 
In the conducted investigations elevated levels 
were demonstrated of TNF-α, IL-1 and IL-17, and 
the levels of cytokines were significantly higher 
than in moderate form of the disease [26]. The 
elevated levels of IL-17, and also of TNF-α and IL-
1β in chronic periodontitis were described earlier 
by other authors [41, 42, 49]. Nevertheless, in this 
study the overproduction of IL-17 and TNF-α and 
of IL-1 was for the first time found to be typical 
of the two clinical forms of chronic periodontitis. 
The obtained results permit to distinguish patients 
with a high cytokine pro-inflammatory response 
from those with a moderate response. Intensity 
of pro-inflammatory cytokine response, high or 
moderate, corresponds to severe and moderate 
clinical form of chronic periodontitis respectively. 
Therefore, it can be concluded that chronic perio-
dontitis is determined by the persisting pro-inflam-
matory response, the intensity of which may be of 
significance for clinical course of the disease. The 
conclusion is supported by the data documenting 
the relationship between progression of articular 
damage in patients with rheumatoid arthritis and 
high production of IL-17 and TNF-α [50]. 
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In order to make the conclusion more credible, 
I have conducted studies on adult patients with 
moderate chronic periodontitis treated with an 
oral probiotic preparation [28]. The investigated 
group included 35 patients, 31 to 46 years of age, 
in whom clinical examination allowed to diagnose 
moderate chronic periodontitis with mean duration 
of the disease ranging from 18 to 27 months. Two 
weeks following hygienization procedures in 19 of 
the patients tablets were administered, containing 
hydrogen peroxide-producing probiotic strain of 
Lactobacillus reuteri. The diet supplement of pro-
biotic tablets for chewing, containing Lactobacillus 
reuteri strain (108 CFU Lactobacillus reuteri ATCC 
PTA 5289, Prodentis), was applied by the patients 
twice daily, following tooth brushing. After comple-
ting the treatment, in the subgroup of participants 
a significant clinical improvement was found in 14 
patients (73.7%), expressed by reduced values of 
clinical indices: SBI (Sulcus Bleeding Index), PPD 
(Periodontal Pocket Depth), CAL (Clinical Attach-
ment Level). Moreover, a reduction was disclosed 
in levels of estimated pro-inflammatory cytokines 
(TNF-α, IL-1fl and IL-17). The results remain in line 
with those of Vivekananda et al. [51] and of Vicario 
et al. [52], documenting reductions in values of the 
indices in patients with moderate chronic perio-
dontitis using probiotic tablets and hygienization 
procedures. Also Twetman et al. using a chewing 
gum containing strains of Lactobacillus reuteri de-
monstrated lowered values of GI and SBI indices 
and reduced levels of TNF-α and IL-8 cytokines 
[53]. Other authors pointed to improved clinical in-
dices in patients with gingivitis [54, 55]. In addition, 
Lin et al. demonstrated that L. reuteri inhibits pro-
duction of pro-inflammatory cytokines [56].
In my studies no clinical improvement was no-
ted in 25% of patients with moderate chronic pe-
riodontitis and levels of estimated pro-inflamma-
tory cytokines (TNF-α, IL-1fl and IL-17) showed no 
significant alterations [28]. This may indicate an 
insufficient colonization of gingival pockets by the 
applied probiotic strain of Lactobacillus reuteri. It 
remains possible that the process of periodontal 
colonization in some patients requires a more pro-
longed period of administering probiotic tablets, 
containing Lactobacillus reuteri strain. In the con-
ducted studies the hydrogen peroxide-producing 
strains of Lactobacillus were shown to be present 
significantly more frequently in patients with mo-
derate chronic periodontitis than in those with se-
vere chronic periodontitis. This indicates that the 
strains may prevent development of the disease. 
Lactobacillus reuteri represents one of the well 
recognised strains of probiotic bacteria with a do-
cumented activity in several bacterial infections 
[4, 6–8, 57, 58]. Reuterin, produced by the strain, 
involves a 3-hydroxypropionaldehyde with a broad 
spectrum of antibacterial activity [59]. It is active 
within a broad spectrum of pH and remains resi-
stant to action of lipo- and proteolytic enzymes 
and it exerts a suppressive effect on synthesis of 
pro-inflammatory cytokines. Reuterin blocks ad-
herence and prevents against colonization by pa-
thogens [60].
Thus, the presented data indicate that admi-
nistration of probiotics in dentistry is advisable, 
particularly in dental caries and in chronic perio-
dontitis in adults. Probiotic agents, containing hy-
drogen peroxide-producing Lactobacillus bacteria 
may exert antagonistic effects against cariopatho-
gens and periopathogens, with the resulting redu-
ced cariogenic process and reduced progression 
of chronic periodontitis. The chronic periodontitis 
is associated with significant concentrations of 
pro-inflammatory cytokines, TNF-α and IL-17 in 
gingival fluid of gingival pockets. Treatment with 
probiotic agents containing Lactobacillus reuteri 
strain leads to significantly reduced levels of the 
cytokines. The observations show for the need of 
further studies in order to implement novel strate-
gies in prophylaxis and therapy of caries and pe-
riodontal diseases.
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